Species: Human

Cell type: Lung Carcinoma

Transgenes: Human sodium iodide symporter (hNIS) with neomycin resistance (Neo) for selection with G418 and firefly luciferase (Fluc) with puromycin resistance (Puro) for selection with puromycin

Media: DMEM, 10% FBS, 1% Pen/Strep, 0.6 mg/mL G418, 1 μg/mL puromycin

Description:

A549-hNIS-Neo/Fluc-Puro is a polyclonal population of the human lung carcinoma cell line A549 (ATCC® CCL-185™) transduced with 1) LV-hNIS-IRES-Neo (LV013) encoding the human sodium iodide symporter (hNIS) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the neomycin resistance gene (Neo) via an internal ribosomal entry site (IRES) and 2) LV-Fluc-P2A-Puro (LV012) encoding firefly luciferase (Fluc) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the puromycin resistance gene (Puro) via a P2A cleavage peptide.

The lentiviral vector used is a self-inactivating (SIN) vector in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).

Mycoplasma Testing: The A549-hNIS-Neo/Fluc-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

Cell Line Authentication: The parental A549 cell line was authenticated and certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 9 STR loci including CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, vWA and sex chromosome marker Amelogenin.

Recommended uses:

In vitro: This is a high hNIS/luciferase expressing cell line suitable for use as a positive control cell line in iodine uptake and bioluminescence assays to verify NIS or luciferase expression respectively in your lentiviral transduced cells.

In vivo: A549 cells form metastases in the lungs of mice post systemic administration. The in vivo growth of these metastases can be monitored using noninvasive, high-resolution 3D PET/SPECT imaging or bioluminescent imaging.

References on NIS imaging:

1. Fruthwirth et al. A whole body dual modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment responses in different. microenvironments. J. Nucl. Med 2014. 55(4): 686-94.

2. Penheiter et al. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral and cell-based therapies. Curr Gene Ther. 2012, 12(1):33-47.

Cell photos: Low- and high-density cell morphology (200X)

NIS Functional Assay (Iodine Uptake): Cells were incubated with ¹²⁵I for 1h in the presence or absence of KClO₄, an inhibitor of NIS-mediated iodine uptake. Radioiodine concentrated within the cells was measured with a gamma counter.

Luciferase Assay: 10⁴, 10⁵, or 10⁶ cells were placed in wells of a 96-well plate and 30 μg/mL of d-luciferin was added to the indicated wells. The plate was immediately imaged using a Xenogen IVIS Spectrum.

Bioluminescent images showing growth of a subcutaneous A549-Fluc tumor in an athymic mouse

10⁷ A549-Fluc-Puro cells (Imanis Life catalog #CL080) were injected subcutaneously into the right flanks of female NCR athymic mice. Mice were imaged at day 0 on the day of cell implantation and subsequently at days 7 and 16 using a Perkin Elmer IVIS® Spectrum system, at 10-15 minutes post intraperitoneal injection of D-luciferin at 150 mg/kg. Tumor size was measured using calipers. Data from a representative mouse (ID#4878) is shown.